Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Cipla
Covington
Julphar
Baxter
Deloitte
Moodys
Farmers Insurance
Healthtrust

Generated: September 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021204

« Back to Dashboard

NDA 021204 describes STARLIX, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the STARLIX profile page.

The generic ingredient in STARLIX is nateglinide. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the nateglinide profile page.
Summary for 021204
Tradename:STARLIX
Applicant:Novartis
Ingredient:nateglinide
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 021204
Mechanism of ActionPotassium Channel Antagonists
Suppliers and Packaging for NDA: 021204
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
STARLIX nateglinide TABLET;ORAL 021204 NDA Novartis Pharmaceuticals Corporation 0078-0351 0078-0351-05 100 TABLET in 1 BOTTLE (0078-0351-05)
STARLIX nateglinide TABLET;ORAL 021204 NDA Novartis Pharmaceuticals Corporation 0078-0352 0078-0352-05 100 TABLET in 1 BOTTLE (0078-0352-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength60MG
Approval Date:Dec 22, 2000TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 15, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
Patent:➤ Try a Free TrialPatent Expiration:Sep 15, 2020Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength120MG
Approval Date:Dec 22, 2000TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 15, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES

Expired US Patents for NDA 021204

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis STARLIX nateglinide TABLET;ORAL 021204-002 Dec 22, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis STARLIX nateglinide TABLET;ORAL 021204-001 Dec 22, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis STARLIX nateglinide TABLET;ORAL 021204-001 Dec 22, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis STARLIX nateglinide TABLET;ORAL 021204-001 Dec 22, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis STARLIX nateglinide TABLET;ORAL 021204-001 Dec 22, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Fuji
Express Scripts
Merck
QuintilesIMS
Federal Trade Commission
Farmers Insurance
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.